Stay updated on Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page.

Latest updates to the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page
- Check2 days agoChange DetectedAn NIH-wide notice about terminology changes during a transition appears above the ClinicalTrials.gov 403 error page.SummaryDifference1%

- Check9 days agoChange DetectedThe footer’s site revision label changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check16 days agoChange DetectedThe footer's ClinicalTrials.gov revision label changed from v3.7.0 to v3.7.1; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study content, indicating access is blocked while the site header and footer remain visible.SummaryDifference20%

- Check58 days agoChange DetectedThe revision tag on the page was updated from v3.6.5 to v3.6.6, representing a small documentation/quality-control update to the study record.SummaryDifference0.1%

- Check80 days agoChange DetectedThe page's revision stamp was updated from v3.6.4 to v3.6.5, reflecting a minor update to the page's versioning. This update does not alter the study details, eligibility criteria, or other content on the page.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page.